

APPROACH TO OBESE PATIENT



NJOUD ALRASHEED

NOUF ALORAINI

AMERAH BIN ZUAIR

RAGHAD ALAJLAN

ROLE PLAY



WHAT IS OBESITY? IS IT THE SAME AS BEING OVERWEIGHT?



- OVERWEIGHT AND OBESITY ARE **DEFINED** AS ABNORMAL OR EXCESSIVE FAT ACCUMULATION THAT MAY IMPAIR HEALTH.
- WORLDWIDE OBESITY HAS NEARLY **TRIPLED** SINCE 1975.
- OBESITY IS **PREVENTABLE**



BUT HOW CAN WE SAY THAT THIS PERSON IS OBESE OR
OVERWEIGHT?



BODY MASS INDEX:

Body Mass Index



WAIST-HIP RATIO:



WOMEN	HEALTH RISK	BODY SHAPE
0.80 or below	Low	Pear
0.81 to 0.85	Moderate	Avocado
0.85+	High	Apple
MEN	HEALTH RISK	BODY SHAPE
0.95 or below	Low	Pear
0.96 to 1.0	Moderate	Avocado
1.0+	High	Apple



WAIST CIRCUMFERENCE:

	Men	Women
Normal	78-94cm	64-80cm
Overweight (Elevated Risk)	94-102cm	80-88cm
Obese (High Risk)	>102cm	>88cm



WHAT IS THE PREVALENCE OF OBESITY IN SAUDI ARABIA?



❑ 2014 **NATIONALLY** (10,735) MALE **24.1%** AND FEMALE **33.5%** > 28.7%. MEMISH ET AL. (2014)

❑ 2014 **RIYADH, JEDDAH, AND AL-KHOBAR** (2,908) OBESITY: MALE = **24.1%**; FEMALES = **14%**


(PREVALENCE OF **OVERWEIGHT** EQUALS **20.8%** AND 19.5%; AND PREVALENCE OF **ABDOMINAL OBESITY** EQUALS TO 30.3% AND 38.7% IN FEMALES AND MALES RESPECTIVELY). AL-HAZZAA ET AL. (2014)

..... AND IF THINGS CONTINUE AS THEY ARE>>>

❑ THE OVERALL OBESITY WILL INCREASE TO **41%** IN MEN AND **78%** IN WOMEN BY 2022. AL-QUWAIDHI ET AL. (2014)



OBESITY HAS BEEN OFFICIALLY RECOGNIZED AS A **DISEASE** BY THE AMERICAN MEDICAL ASSOCIATION, AN ACTION THAT COULD PUT MORE EMPHASIS ON THE HEALTH CONDITION BY DOCTORS AND INSURANCE COMPANIES IN ORDER TO MINIMIZE ITS EFFECTS.



CAUSES OF OBESITY



CAUSES OF OBESITY:

BEHAVIORAL / PSYCHOLOGICAL

- PHYSICAL INACTIVITY
- UNHEALTHY DIET
- SMOKING CESSATION
- ONGOING BINGE EATING DISORDER*,
- DEPRESSION

ENVIRONMENT

- LOW INCOME
- CULTURE


ENDOCRINE

- PCOS
- HYPOTHYROIDISM,
- CUSHING

DRUGS

- STEROIDS,
- ANTIPSYCHOTICS (E.G. OLANZAPINE),
- CONTRACEPTIVES (ESPECIALLY DEPO-INJECTIONS),
- SULFONYLUREAS ,
- INSULIN

GENETIC



HOW CAN WE PREVENT
OBESITY?



PRIMARY PREVENTION:

EDUCATION

A) MAINTAINING A BALANCED DIET AND A HEALTHY BEHAVIOR

SPECIAL CONSIDERATION FOR CHILDREN:

- AVOID USING FOOD AS A REWARD. - ENCOURAGEMENT OF HEALTHY FOOD CONSUMPTION.

B) EXERCISING AND ACTIVE LIFE STYLE:

WALK AND EXERCISE FOR 30 MINUTE OR MORE, 5 DAYS A WEEK. - REDUCE TIME SPENT IN FRONT OF TV, COMPUTER, AND MOBILES.

C) BREAST FEEDING:

A RECENT SYSTEMATIC REVIEW HOWEVER FOUND ONLY A 10 PERCENT REDUCTION OF OVERWEIGHT CHILDREN WITH LONG TERM BREAST FEEDING



SECONDARY PREVENTION:

A) EXERCISE

B) DIET

C) DRUG MANAGEMENT

E) BARIATRIC SURGERY



TERTIARY PREVENTION:

DECREASING THE PROGRESSION TO MORE SEVERE OBESITY

- REDUCING THE LIKELIHOOD OF ASSOCIATED MUSCULOSKELETAL, METABOLIC, OR VASCULAR DISORDERS (E.G., OSTEOARTHRITIS, DIABETES, OR CARDIOVASCULAR DISEASE).






HEALTH RISKS OF OBESITY



PEOPLE WHO HAVE OBESITY, COMPARED TO THOSE WITH A NORMAL OR HEALTHY WEIGHT, ARE AT INCREASED RISK FOR MANY SERIOUS DISEASES AND HEALTH CONDITIONS

 Psychosocial

Poor Self-esteem
Depression
Eating Disorders

Neurological 

Pseudotumor cerebri

 Pulmonary


Sleep Apnoea
Asthma
Exercise Intolerance

Cardiovascular 

Dyslipidaemia
Hypertension
Coagulopathy
Chronic Inflammation
Endothelial Dysfunction

 Gastrointestinal

Gallstones
Steatohepatitis

Endocrine 

Type 2 diabetes
Precocious Puberty
Polycystic Ovary Syndrome(girls)
Hypogonadism(boys)


 Renal

Glomeruloscl

 Musculoskeletal

Flat Feet
Forearm Fracture
Blount's Disease
Slipped Capital Femoral Epiphysis



 : Physically

 : Psychologically



- AN IMPORTANT NEED FOR PRIMARY CARE PHYSICIANS IS TO IDENTIFY THESE COMORBIDITIES AND THE RESULTING OUTCOMES.
- AWARENESS OF THE DISORDERS WITH THE STRONGEST ASSOCIATIONS WITH OBESITY IS IMPORTANT TO ALLOW EARLY DIAGNOSIS AND TREATMENT, AND TO IDENTIFY THE PATIENTS MOST LIKELY TO BENEFIT FROM WEIGHT LOSS.
- EARLY IDENTIFICATION AND ASSESSMENT OF RISKS SO THAT APPROPRIATE INTERVENTIONS CAN BE IMPLEMENTED TO REDUCE RISK AND MORTALITY.




HIGH BLOOD PRESSURE IS DEFINED AS:

MEAN SYSTOLIC BLOOD PRESSURE ≥ 140 MM HG, OR MEAN DIASTOLIC BLOOD PRESSURE ≥ 90 MM HG,

OR CURRENTLY TAKING ANTI- HYPERTENSIVE MEDICATION.

THE PATHOPHYSIOLOGY UNDERLYING THE DEVELOPMENT OF HYPERTENSION ASSOCIATED WITH OBESITY INCLUDES SODIUM RETENTION AND ASSOCIATED INCREASES IN VASCULAR RESISTANCE, BLOOD VOLUME, AND CARDIAC OUTPUT.

Figure 2. NHANES III Age-Adjusted Prevalence of Hypertension* According to Body Mass Index



THE DIRECT AND INDEPENDENT ASSOCIATION BETWEEN BLOOD PRESSURE AND BMI OR WEIGHT HAS BEEN SHOWN IN NUMEROUS CROSS-SECTIONAL STUDIES, INCLUDING THE LARGE INTERNATIONAL STUDY OF SALT (INTERSALT) CARRIED OUT IN MORE THAN 10,000 MEN AND WOMEN. INTERSALT REPORTED THAT A 10 KG (22 LB) HIGHER BODY WEIGHT IS ASSOCIATED WITH 3.0 MM HG HIGHER SYSTOLIC AND 2.3 MM HG HIGHER DIASTOLIC BLOOD PRESSURE. 6 THESE DIFFERENCES IN BLOOD PRESSURE TRANSLATE INTO AN ESTIMATED

12 PERCENT INCREASED RISK FOR CHD AND 24 PERCENT INCREASED RISK FOR STROKE.

CORONARY HEART DISEASE



-RECENT STUDIES HAVE SHOWN THAT THE RISKS OF NONFATAL MYOCARDIAL INFARCTION AND CHD DEATH INCREASE WITH INCREASING LEVELS OF BMI.

-WEIGHT GAINS OF 5 TO 8 KG (11 TO 17.6 LB) INCREASED CHD RISK (NONFATAL MYOCARDIAL INFARCTION AND CHD DEATH) BY 25 PERCENT

-RISKS ARE LOWEST IN MEN AND WOMEN WITH BMIS OF 22 OR LESS AND INCREASE WITH EVEN MODEST ELEVATIONS OF BMI.

DYSLIPIDEMIA



HIGH TOTAL CHOLESTEROL ≥ 240 MG/D

HIGH TRIGLYCERIDES

LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL

NORMAL TO ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL ≥ 160 MG/DL.

Figure 3. NHANES III Age-Adjusted Prevalence of High Blood Cholesterol According to Body Mass Index






Figure 3. NHANES III Age-Adjusted Prevalence of High Blood Cholesterol According to Body Mass Index




DIABETES MELLITUS



-THE RELATIVE RISK OF DIABETES INCREASES BY APPROXIMATELY **25 PERCENT** FOR EACH ADDITIONAL UNIT OF BMI OVER 22 KG/M² .

-BOTH CROSS-SECTIONAL AND LONGITUDINAL STUDIES SHOW THAT ABDOMINAL OBESITY IS A MAJOR RISK FACTOR FOR TYPE 2 DIABETES.

STROKE



ISCHEMIC STROKE RISK IS 75 PERCENT HIGHER IN WOMEN WITH BMI > 27, AND 137 PERCENT HIGHER IN WOMEN WITH A BMI > 32, COMPARED WITH WOMEN HAVING A BMI < 21.

OSTEOARTHRITIS



-INDIVIDUALS WHO ARE OVERWEIGHT OR OBESE INCREASE THEIR RISK FOR THE DEVELOPMENT OF OSTEOARTHRITIS.

-THE ASSOCIATION BETWEEN INCREASED WEIGHT AND THE RISK FOR DEVELOPMENT OF KNEE OSTEOARTHRITIS IS STRONGER IN WOMEN THAN IN MEN.

-IN A STUDY OF TWIN MIDDLE-AGED WOMEN, IT WAS ESTIMATED THAT FOR EVERY KILOGRAM INCREASE OF WEIGHT, THE RISK OF DEVELOPING OSTEOARTHRITIS INCREASES BY 9 TO 13 PERCENT. THE TWINS WITH KNEE OSTEOARTHRITIS WERE GENERALLY 3 TO 5 KG (6.6 TO 11 LB) HEAVIER THAN THE CO-TWIN WITH NO DIS-EASE.



SLEEP APNEA

i wish my job
was sleeping



-THE MAJOR PATHOPHYSIOLOGIC CONSEQUENCES OF SEVERE SLEEP APNEA INCLUDE ARTERIAL HYPOXEMIA, RECURRENT AROUSALS FROM SLEEP, INCREASED SYMPATHETIC TONE, PULMONARY AND SYSTEMIC HYPERTENSION, AND CARDIAC ARRHYTHMIAS.

-MOST PEOPLE WITH SLEEP APNEA HAVE A $BMI > 30$.


LARGE NECK GIRTH IN BOTH MEN AND WOMEN WHO SNORE IS HIGHLY PREDICTIVE OF SLEEP APNEA.

CANCER

BEING OVERWEIGHT CAN CAUSE 13 TYPES OF CANCER

●●● Larger circles indicate cancers with more UK cases linked to being overweight or obese

○ Number of linked cases are currently being calculated and will be available in 2017



LET'S BEAT CANCER SOONER
cruk.org



OBESITY AND WOMEN'S REPRODUCTIVE HEALTH

MENSTRUAL FUNCTION AND FERTILITY

- OBESITY IN PREMENOPAUSAL WOMEN IS ASSOCIATED WITH MENSTRUAL IRREGULARITY AND AMENORRHEA..
- A CASE CONTROL STUDY SUGGESTED THAT THE GREATER THE BMI AT AGE 18 YEARS, EVEN AT LEVELS LOWER THAN THOSE CONSIDERED OBESE, THE GREATER THE RISK OF SUBSEQUENT OVULATORY INFERTILITY.
- THE MOST PROMINENT CONDITION ASSOCIATED WITH ABDOMINAL OBESITY IS POLYCYSTIC OVARIAN SYNDROME.

PREGNANCY

- HIGHER PREPREGNANCY WEIGHTS HAVE BEEN SHOWN TO INCREASE THE RISK OF LATE FETAL DEATHS.
- OBESITY DURING PREGNANCY IS ASSOCIATED WITH INCREASED MORBIDITY FOR BOTH THE MOTHER AND THE CHILD. A TENFOLD INCREASE IN THE PREVALENCE OF HYPERTENSION AND A 10 PERCENT INCIDENCE OF GESTATIONAL DIABETES HAVE BEEN REPORTED IN OBESE PREGNANT WOMEN.



PSYCHOSOCIAL ASPECTS OF OVERWEIGHT AND OBESITY

-SOCIAL STIGMATIZATION

-PSYCHOPATHOLOGY

OBESE INDIVIDUALS SEEKING TREATMENT REPORTED **MORE** PSYCHOPATHOLOGY AND BINGE EATING COMPARED TO THE OTHER GROUPS.

-BINGE EATING DISORDER.

IT IS ESTIMATED TO OCCUR IN **20 TO 50 PERCENT** OF INDIVIDUALS WHO SEEK SPECIALIZED OBESITY TREATMENT.

-BODY IMAGE PERCEPTIONS.

IN SOME GROUPS OF OBESE PERSONS, THESE INDIVIDUALS ARE **MORE** DISSATISFIED AND PREOCCUPIED WITH THEIR PHYSICAL APPEARANCE, AND AVOID MORE SOCIAL SITUATIONS DUE TO THEIR APPEARANCE



DON'T BE SAD WINNIE





THE 5AS APPROACH*


Figure 1. The 5 As framework*



*In Canada, the United States, the United Kingdom, and Australia, the 5 As might represent slightly different verbs (eg, *assist* in Canada and the United States is *arrange* in Australia).

THE EVIDENCE BASED APPROACH TO DECREASE WEIGHT

Figure 2. Proposed model for the management of obesity within each consultation




THE INITIAL GOAL OF WEIGHT LOSS THERAPY SHOULD BE TO REDUCE BODY WEIGHT BY APPROXIMATELY 10 PERCENT FROM BASELINE. WITH SUCCESS, FURTHER WEIGHT LOSS CAN BE ATTEMPTED IF INDICATED THROUGH FURTHER ASSESSMENT.

WEIGHT LOSS SHOULD BE ABOUT 1 TO 2 LB/WEEK FOR A PERIOD OF 6 MONTHS, WITH THE SUBSEQUENT STRATEGY BASED ON THE AMOUNT OF WEIGHT LOST

THE EVIDENCE BASED APPROACH TO DECREASE WEIGHT

SO, WHAT IS THE PLAN ?



- 1 Lifestyle Modification**
Weight loss and weight maintenance therapy should employ the combination of LCDs, increased physical activity, and behavior therapy. Evidence Category A
- 2 Pharmacotherapy**
Weight loss drugs approved by the FDA may be used as part of a comprehensive weight loss program
- 3 Surgical**
Weight loss surgery is an option for carefully selected patients with clinically severe obesity

1) LIFESTYLE MODIFICATION

DIET :

LCDS ARE RECOMMENDED FOR WEIGHT LOSS IN OVERWEIGHT AND OBESE PERSONS. EVIDENCE CATEGORY A. REDUCING FAT AS PART OF AN **LCD** IS A PRACTICAL WAY TO REDUCE CALORIES.

REDUCING DIETARY FAT ALONE WITHOUT REDUCING CALORIES IS **NOT SUFFICIENT** FOR WEIGHT LOSS. HOWEVER, REDUCING DIETARY FAT, ALONG **WITH** REDUCING DIETARY CARBOHYDRATES, CAN FACILITATE CALORIC REDUCTION.

A DIET THAT IS INDIVIDUALLY PLANNED TO HELP CREATE A DEFICIT OF **500 TO 1,000 KCAL/DAY** SHOULD BE AN INTEGRAL PART OF ANY PROGRAM AIMED AT ACHIEVING A WEIGHT LOSS OF 1 TO 2 LB/WEEK.




1) LIFESTYLE MODIFICATION

PHYSICAL ACTIVITY :

PHYSICAL ACTIVITY IS RECOMMENDED AS PART OF A COMPREHENSIVE WEIGHT LOSS THERAPY AND WEIGHT CONTROL PROGRAM BECAUSE IT: (1) MODESTLY CONTRIBUTES TO WEIGHT LOSS IN OVERWEIGHT AND OBESE ADULTS , (2) MAY DECREASE ABDOMINAL FAT (3) INCREASES CARDIORESPIRATORY FITNESS , AND (4) MAY HELP WITH MAINTENANCE OF WEIGHT LOSS .

PHYSICAL ACTIVITY SHOULD BE AN INTEGRAL PART OF WEIGHT LOSS THERAPY AND WEIGHT MAINTENANCE. INITIALLY, MODERATE LEVELS OF PHYSICAL ACTIVITY FOR 30 TO 45 MINUTES, 3 TO 5 DAYS A WEEK, SHOULD BE ENCOURAGED. ALL ADULTS SHOULD SET A LONG-TERM GOAL TO ACCUMULATE AT LEAST 30 MINUTES OR MORE OF MODERATE-INTENSITY PHYSICAL ACTIVITY ON MOST, AND PREFERABLY ALL, DAYS OF THE WEEK.



1) LIFESTYLE MODIFICATION

15 ARTICLES REVIEWED AND INCLUDED IN THE GUIDELINES CONTAIN STRONG EVIDENCE THAT THE COMBINATION OF A REDUCED-CALORIE DIET AND INCREASED PHYSICAL ACTIVITY PRODUCES GREATER WEIGHT LOSS THAN DIET ALONE OR PHYSICAL ACTIVITY ALONE .



BEHAVIOUR THERAPY: IS A USEFUL ADJUNCT WHEN INCORPORATED INTO TREATMENT FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

2) PHARMACOTHERAPY

WEIGHT LOSS DRUGS APPROVED BY THE FDA MAY BE USED AS PART OF A COMPREHENSIVE WEIGHT LOSS PROGRAM, INCLUDING DIETARY THERAPY AND PHYSICAL ACTIVITY FOR PATIENTS WITH A BMI OF ≥ 30 WITH NO CONCOMITANT OBESITY-RELATED RISK FACTORS OR DISEASES, AND FOR PATIENTS WITH A BMI OF ≥ 27 WITH CONCOMITANT OBESITY-RELATED RISK FACTORS OR DISEASES. WEIGHT LOSS DRUGS SHOULD NEVER BE USED WITHOUT CONCOMITANT LIFESTYLE MODIFICATIONS. CONTINUAL ASSESSMENT OF DRUG THERAPY FOR EFFICACY AND SAFETY IS NECESSARY. IF THE DRUG IS EFFICACIOUS IN HELPING THE PATIENT TO LOSE AND/OR MAINTAIN WEIGHT LOSS AND THERE ARE NO SERIOUS ADVERSE EFFECTS, IT CAN BE CONTINUED. IF NOT, IT SHOULD BE DISCONTINUED.



WHAT ARE THE FDA APPROVED
DRUGS FOR OBESITY TREATMENT?



<u>NAME</u>	<u>MOA</u>	<u>EFFECTS</u>	<u>SIDE EFFECTS</u>	<u>CONTRAINDICATIONS</u>
ORLISTAT	Peripherally acting pancreatic lipase inhibitor; reduces absorption of ingested fat	Orlistat plus behavioral counseling doubled weight loss seen with placebo/counseling. Progression to diabetes reduced.	Gastrointestinal (diarrhea, flatulence), especially if large amounts fat are ingested.	Pregnancy, cholestasis, chronic malabsorption syndromes, coadministration with cyclosporine. Can increase urinary oxalate and predispose to kidney stones.
PHENTERMINE TOPIRAMATE ER	Combination of appetite-suppressant sympathomimetic amine and anticonvulsant	Additive effect of drug combination leads to more weight loss than either agent alone; reduced progression to type 2 diabetes	Paresthesia, dizziness, dysgeusia, insomnia, constipation, dry mouth.	pregnancy should be ruled out before starting the medication, and women of childbearing age should use contraception and have monthly pregnancy testing during use.
LORCASERIN	Selective serotonin 2c (5HT-2c) receptor agonist; stimulates 5HT-2c receptors (not other serotonin receptors) in the appetite center of the brain.	Average weight loss 8%; improved blood pressure, lipids, glycemic control.	Headache, dizziness, fatigue, nausea, dry mouth, constipation; hypoglycemia with concomitant antidiabetic agents.	Pregnancy (Risk for serotonergic syndrome/neuroleptic malignant syndrome if the patient is taking serotonergic or antidopaminergic agent)
NALTREXONE SR/BUPROPION SR	Effects may occur in the hypothalamic appetite center or the mesocorticolimbic dopamine system and other brain areas related to reward-driven behaviors	Long-term use; combination produces > 8% weight loss (diminished appetite and cravings); > 12% weight loss when combined with intensive lifestyle intervention. Also improves glycemic control.	Nausea, constipation, diarrhea, headache; most resolve in days to weeks and do not recur.	Uncontrolled hypertension; seizure disorders; chronic opioid use; MAOI use; pregnancy
LIRAGLUTIDE 3.0 MG	Glucagon-like peptide 1 receptor agonist.	Achieved 9% weight loss; 71% maintained at 3 years. Reduced progression to diabetes by 80%.	Nausea; gastrointestinal symptoms	History of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, acute pancreatitis, pregnancy, breastfeeding.

3) SURGICAL THERAPY



WEIGHT LOSS SURGERY IS AN OPTION FOR CAREFULLY SELECTED PATIENTS WITH CLINICALLY SEVERE OBESITY (BMI ≥ 40 OR ≥ 35 WITH COMORBID CONDITIONS) WHEN LESS INVASIVE METHODS OF WEIGHT LOSS HAVE FAILED AND THE PATIENT IS AT HIGH RISK FOR OBESITY-ASSOCIATED MORBIDITY OR MORTALITY.



**Adjustable
Gastric Band
(AGB)**



**Roux-en-Y
Gastric Bypass
(RYGB)**



**Vertical Sleeve
Gastrectomy
(VSG)**




**Biliopancreatic
Diversion With a
Duodenal Switch
(BPD-DS)**

WHAT ARE THE COMMONEST TYPES OF BARIATRIC SURGERIES ?

WEIGHT LOSS MAINTENANCE

A WEIGHT MAINTENANCE PROGRAM SHOULD BE A PRIORITY AFTER THE INITIAL 6 MONTHS OF WEIGHT LOSS THERAPY.





WHAT IS OUR ROLE AS A MEDICAL STUDENTS AND HEALTH TEAM??

ROLE OF MEDICAL STUDENTS AND HEALTH TEAM IN THE COMMUNITY



- SERVE AS LEADERS AND ROLE MODELS, WITHIN ONE'S PRACTICE AND COMMUNITY, TO ENCOURAGE HEALTHY CHANGES IN PHYSICAL ACTIVITY, NUTRITION, AND THE BUILT ENVIRONMENT.
- INTERPRETING BMI PERCENTILE FOR AGE
- COUNSELING ON NUTRITION AND PHYSICAL ACTIVITY
- MOTIVATIONAL INTERVIEWING SKILLS
- EDUCATE THE PUBLIC

WHAT IS THE ROLE OF SCHOOLS??



ROLE OF SCHOOLS



- EDUCATE THE PARENTS
- EDUCATE THE CHILDREN
- SCREENING
- MORE NUTRITIOUS FOOD
- PHYSICAL ACTIVITY
- HEALTH SERVICES
- HEALTH EDUCATION







sometimes
the smallest
things take
up the most
room in your
heart



-winnie the pooh

MCQ



<https://www.mentimeter.com/s/9672b718c10d22db890635a597d54a60/49c65b403a4d/edit>

REFERENCES:

[HTTP://WWW.WHO.INT/MEDIACENTRE/FACTSHEETS/FS311/EN/](http://www.who.int/mediacentre/factsheets/fs311/en/)

[HTTP://OBESITY.IMEDPUB.COM/A-REVIEW-OF-PREVALENCE-OF-OBESITY-IN-SAUDI-ARABIA.PHP?AID=17699](http://obesity.imedpub.com/a-review-of-prevalence-of-obesity-in-saudi-arabia.php?aid=17699)

[HTTPS://WWW.NHLBI.NIH.GOV/FILES/DOCS/GUIDELINES/OB_GDLNS.PDF](https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf)

NHLBI OBESITY EDUCATION INITIATIVE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION, AND TREATMENT OF OBESITY IN ADULTS (US). CLINICAL GUIDELINES ON THE IDENTIFICATION, EVALUATION, AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS: THE EVIDENCE REPORT. BETHESDA (MD): NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; 1998 SEP. SUMMARY OF EVIDENCE-BASED RECOMMENDATIONS. AVAILABLE FROM:

[HTTPS://WWW.NCBI.NLM.NIH.GOV/BOOKS/NBK2009/](https://www.ncbi.nlm.nih.gov/books/NBK2009/)

STURGISS E, VAN WEEL C. THE 5 AS FRAMEWORK FOR OBESITY MANAGEMENT: DO WE NEED A MORE INTRICATE MODEL? *CANADIAN FAMILY PHYSICIAN*. 2017;63(7):506-508 [HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/PMC5507219/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507219/)

FDA APPROVED DRUGS FOR OBESITY [HTTPS://WWW.MEDSCAPE.COM/VIEWARTICLE/876411_2](https://www.medscape.com/viewarticle/876411_2)

GUIDE TO WEIGHT LOSS SURGERIES

[HTTPS://WWW.MAYOCLINIC.ORG/TESTS-PROCEDURES/BARIATRIC-SURGERY/IN-DEPTH/WEIGHT-LOSS-SURGERY/ART-20045334](https://www.mayoclinic.org/tests-procedures/bariatric-surgery/in-depth/weight-loss-surgery/art-20045334)

THANK YOU
ANY QUESTIONS?

